tamoxifen

Overview

Tamoxifen is a selective estrogen receptor modulator (SERM) used as adjuvant and metastatic treatment in hormone receptor-positive breast cancer. It is also a known risk factor for endometrial pathology including endometrial polyps with KRAS mutations.

Evidence in the corpus

• No patients among the 23 WGS-profiled endometrial polyps had been on tamoxifen, so the association between tamoxifen use and KRAS-mutated polyps (reported in prior literature) could not be tested in this cohort; authors flag tamoxifen as a known risk factor for endometrial polyps and KRAS mutations in polyps based on external literature PMID:28445112.

Resistance mechanisms

• Not reported in corpus.

Cancer types (linked)

• UCEC (endometrial polyp context)

Sources

• PMID:28445112 — Endometrial polyp WGS study (n=23); tamoxifen cited as known risk factor for KRAS-mutated endometrial polyps; not represented in this cohort.

This page was processed by crosslinker on 2026-05-14.